Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial

The FDA has granted Neuralstem approval to advance to the final stage of its multi-phased safety trial of its neural stem cell therapy in ALS patients. Review of safety data from the first twelve patients receiving lumbar injections convinced the FDA to allow Neuralstem to move forward with enrolling the last six patients in the Phase I trial, who will receive injections into the cervical spinal cord. Success in this final phase will be critical for follow-up (Phase II) efficacy studies.

Click here to read more.

Share this: